Leerink Partnrs Forecasts McKesson's Q1 Earnings (NYSE:MCK)

McKesson Co. (NYSE:MCK - Free Report) - Equities research analysts at Leerink Partnrs increased their Q1 2026 earnings per share estimates for shares of McKesson in a report issued on Friday, May 9th. Leerink Partnrs analyst M. Cherny now expects that the company will earn $8.73 per share for the quarter, up from their previous estimate of $8.34. The consensus estimate for McKesson's current full-year earnings is $32.77 per share. Leerink Partnrs also issued estimates for McKesson's Q2 2026 earnings at $8.27 EPS, Q3 2026 earnings at $9.39 EPS and FY2028 earnings at $48.22 EPS.

McKesson (NYSE:MCK - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported $10.12 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $9.83 by $0.29. The business had revenue of $90.82 billion for the quarter, compared to analysts' expectations of $94 billion. McKesson had a negative return on equity of 181.26% and a net margin of 0.82%. The firm's quarterly revenue was up 18.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $6.18 EPS.

A number of other equities analysts have also recently weighed in on the company. Cfra Research cut McKesson from a "moderate buy" rating to a "hold" rating in a report on Friday, April 4th. StockNews.com cut McKesson from a "strong-buy" rating to a "buy" rating in a research note on Friday, February 14th. Wells Fargo & Company lifted their price target on McKesson from $641.00 to $691.00 and gave the stock an "equal weight" rating in a research note on Friday, March 14th. Morgan Stanley lifted their price target on McKesson from $642.00 to $745.00 and gave the stock an "overweight" rating in a research note on Wednesday, April 2nd. Finally, Bank of America lifted their price target on McKesson from $755.00 to $800.00 and gave the stock a "buy" rating in a research note on Friday. Three analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, McKesson currently has a consensus rating of "Moderate Buy" and an average price target of $686.69.

McKesson Stock Up 0.6%

NYSE:MCK opened at $694.12 on Monday. The business's 50-day moving average price is $678.24 and its two-hundred day moving average price is $621.72. McKesson has a twelve month low of $464.42 and a twelve month high of $728.48. The stock has a market cap of $86.99 billion, a P/E ratio of 31.78, a PEG ratio of 1.29 and a beta of 0.53.

Institutional Trading of McKesson

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. ST Germain D J Co. Inc. boosted its stake in McKesson by 350.0% during the fourth quarter. ST Germain D J Co. Inc. now owns 117 shares of the company's stock valued at $67,000 after buying an additional 91 shares during the last quarter. Graypoint LLC boosted its stake in McKesson by 3.9% during the fourth quarter. Graypoint LLC now owns 1,006 shares of the company's stock valued at $573,000 after buying an additional 38 shares during the last quarter. Czech National Bank boosted its stake in McKesson by 4.2% during the fourth quarter. Czech National Bank now owns 27,524 shares of the company's stock valued at $15,686,000 after buying an additional 1,108 shares during the last quarter. Brookstone Capital Management boosted its stake in McKesson by 42.8% during the fourth quarter. Brookstone Capital Management now owns 10,473 shares of the company's stock valued at $5,969,000 after buying an additional 3,137 shares during the last quarter. Finally, Capital Investment Advisors LLC boosted its stake in McKesson by 29.0% during the fourth quarter. Capital Investment Advisors LLC now owns 2,379 shares of the company's stock valued at $1,356,000 after buying an additional 535 shares during the last quarter. Hedge funds and other institutional investors own 85.07% of the company's stock.

Insider Transactions at McKesson

In related news, EVP Leann B. Smith sold 188 shares of the company's stock in a transaction on Wednesday, February 12th. The stock was sold at an average price of $609.59, for a total transaction of $114,602.92. Following the completion of the sale, the executive vice president now owns 1,051 shares in the company, valued at approximately $640,679.09. This represents a 15.17% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Brian S. Tyler sold 8,961 shares of the company's stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $597.99, for a total value of $5,358,588.39. Following the completion of the sale, the chief executive officer now owns 60,664 shares of the company's stock, valued at approximately $36,276,465.36. The trade was a 12.87% decrease in their position. The disclosure for this sale can be found here. Insiders sold 18,110 shares of company stock worth $10,855,706 over the last quarter. 0.11% of the stock is currently owned by insiders.

McKesson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, July 1st. Stockholders of record on Monday, June 2nd will be paid a $0.71 dividend. This represents a $2.84 annualized dividend and a dividend yield of 0.41%. The ex-dividend date of this dividend is Monday, June 2nd. McKesson's dividend payout ratio is currently 13.00%.

McKesson Company Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.